JP2009509562A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009509562A5 JP2009509562A5 JP2008534069A JP2008534069A JP2009509562A5 JP 2009509562 A5 JP2009509562 A5 JP 2009509562A5 JP 2008534069 A JP2008534069 A JP 2008534069A JP 2008534069 A JP2008534069 A JP 2008534069A JP 2009509562 A5 JP2009509562 A5 JP 2009509562A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- optionally
- residue
- helix
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 24
- 108020004707 nucleic acids Proteins 0.000 claims 6
- 150000007523 nucleic acids Chemical class 0.000 claims 6
- 102000039446 nucleic acids Human genes 0.000 claims 6
- 239000013604 expression vector Substances 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 235000001014 amino acid Nutrition 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 230000009693 chronic damage Effects 0.000 claims 2
- 208000017520 skin disease Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 108010069514 Cyclic Peptides Proteins 0.000 claims 1
- 102000001189 Cyclic Peptides Human genes 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- 206010014989 Epidermolysis bullosa Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 230000007881 chronic fibrosis Effects 0.000 claims 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000002595 magnetic resonance imaging Methods 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 230000003287 optical effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
- 238000002603 single-photon emission computed tomography Methods 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 238000004611 spectroscopical analysis Methods 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 238000003325 tomography Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0520068A GB0520068D0 (en) | 2005-10-03 | 2005-10-03 | av peptide ligand |
| GB0520068.8 | 2005-10-03 | ||
| PCT/GB2006/003673 WO2007039728A2 (en) | 2005-10-03 | 2006-10-03 | AVß6 PEPTIDE LIGANDS AND THEIR USES |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009509562A JP2009509562A (ja) | 2009-03-12 |
| JP2009509562A5 true JP2009509562A5 (https=) | 2009-11-12 |
| JP5449774B2 JP5449774B2 (ja) | 2014-03-19 |
Family
ID=35395162
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008534069A Active JP5449774B2 (ja) | 2005-10-03 | 2006-10-03 | αｖβ６ペプチドリガンド及びその活用 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US8383593B2 (https=) |
| EP (1) | EP1957522B1 (https=) |
| JP (1) | JP5449774B2 (https=) |
| CA (2) | CA2624618C (https=) |
| ES (1) | ES2638439T3 (https=) |
| GB (1) | GB0520068D0 (https=) |
| WO (1) | WO2007039728A2 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0520068D0 (en) | 2005-10-03 | 2005-11-09 | Cancer Res Technology | av peptide ligand |
| TW200815474A (en) | 2006-08-03 | 2008-04-01 | Astrazeneca Ab | Antibodies alphaVbeta6 and uses thereof |
| GB0718843D0 (en) | 2007-09-26 | 2007-11-07 | Cancer Rec Tech Ltd | Materials and methods relating to modifying the binding of antibodies |
| MX342270B (es) * | 2010-02-18 | 2016-09-21 | The Regents Of The Univ Of California * | ANTICUERPO NEUTRALIZANTE DE LA INTEGRINA AVß8. |
| WO2013025261A2 (en) * | 2011-04-06 | 2013-02-21 | Georgia Tech Research Corporation | Fluorogenic peptide probes and assays |
| WO2013078250A2 (en) * | 2011-11-22 | 2013-05-30 | The Board Of Trustees Of The Leland Stanford Junior University | Cystine knot peptides that bind alpha-v-beta-6 integrin |
| US9403877B2 (en) | 2012-01-24 | 2016-08-02 | Inter-K Pty Limited | Peptide agents for cancer therapy |
| US9282120B2 (en) * | 2013-02-01 | 2016-03-08 | Vidder, Inc. | Securing communication over a network using client integrity verification |
| GB201311031D0 (en) * | 2013-06-20 | 2013-08-07 | Queen Mary & Westfield College | Method |
| JP6789823B2 (ja) * | 2014-04-15 | 2020-11-25 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 両末端ｐｅｇ化インテグリン結合性ペプチドおよびその使用方法 |
| GB201513540D0 (en) | 2015-07-31 | 2015-09-16 | King S College London | Therapeutic agents |
| EP3468984A4 (en) * | 2016-06-13 | 2020-03-11 | The Regents of the University of California | ALPHA (V) BETA (6) BINDING PEPTIDES AND METHODS OF USE THEREOF |
| BR112018076184A2 (pt) * | 2016-06-16 | 2019-03-26 | The University Of Liverpool | composição sólida, composição farmacêutica ou veterinária na forma injetável, formulação intramuscularmente injetável, formulação subcutaneamente injetável, dispersão aquosa, dispersão oleosa, processos para preparar uma composição sólida, uma dispersão aquosa e uma dispersão oleosa, métodos para tratar e/ou prevenir uma infecção parasítica ou fúngica e para prevenir malária, e, kit para preparação de uma formulação líquida estéril de nanopartículas de atovaquona para injeção. |
| ES3023938T3 (en) | 2016-09-29 | 2025-06-03 | Univ California | Neutralizing antibodies to the alpha v beta 8 integrin complex for immunotherapy |
| SI3535397T1 (sl) * | 2016-11-01 | 2022-04-29 | Arrowhead Pharmaceuticals, Inc. | Ligandi alfa-V beta-6 integrina in njihove uporabe |
| GB201706472D0 (en) * | 2017-04-24 | 2017-06-07 | Cancer Res Tech Ltd | Tumour-targeting peptide variants |
| JP7445594B2 (ja) | 2017-11-01 | 2024-03-07 | アローヘッド ファーマシューティカルズ インコーポレイテッド | インテグリンリガンドおよびその使用 |
| GB201802539D0 (en) * | 2018-02-16 | 2018-04-04 | Univ College Cardiff Consultants Ltd | Modified adenoviruses |
| EP3846858A4 (en) * | 2018-09-07 | 2022-10-19 | The Regents of the University of California | Alpha(v)beta(6) integrin-binding peptides and methods of use thereof |
| AU2020370362A1 (en) * | 2019-10-25 | 2022-06-02 | Children's Medical Center Corporation | Computational design of alpha(v) beta (6) integrin binding proteins |
| WO2021094608A1 (en) * | 2019-11-15 | 2021-05-20 | Ospedale San Raffaele S.R.L. | Chromogranin a-derived peptides and uses thereof |
| US12486502B2 (en) | 2021-04-08 | 2025-12-02 | Arrowhead Pharmaceuticals, Inc. | RNAi agents for inhibiting expression of receptor for advanced glycation end-products, compositions thereof, and methods of use |
| WO2022221144A1 (en) * | 2021-04-12 | 2022-10-20 | University Of Washington | Engineered peptides for αvβ6 integrin binding and related methods of use and synthesis |
| CN115010949B (zh) * | 2022-07-12 | 2024-02-13 | 华熙生物科技股份有限公司 | 促渗物、护肤品组合物以及化妆品 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8301928D0 (en) | 1983-01-24 | 1983-02-23 | Nicholson B H | Process for producing polypeptides |
| JPS60103596A (ja) * | 1983-11-11 | 1985-06-07 | Toshiba Corp | サンプル・ホ−ルド回路 |
| AUPM411994A0 (en) * | 1994-02-25 | 1994-03-24 | Deakin Research Limited | Epitopes |
| EP1140989A1 (de) | 1998-12-19 | 2001-10-10 | MERCK PATENT GmbH | Inhibitoren des integrins alpha(v) beta(6) |
| DE19929410A1 (de) * | 1999-06-26 | 2000-12-28 | Merck Patent Gmbh | Inhibitoren des Integrins avß6 |
| DE19933173A1 (de) * | 1999-07-15 | 2001-01-18 | Merck Patent Gmbh | Cyclische Peptidderivate als Inhibitoren des Integrins alpha¶v¶beta¶6¶ |
| JP2003534558A (ja) * | 2000-05-26 | 2003-11-18 | グラクソ グループ リミテッド | ＬＡＰ（潜在型結合ペプチド）とインテグリンαｖβ３との間の相互作用のモジュレーターを同定する方法及びその医学的使用 |
| US20030031648A1 (en) * | 2000-11-28 | 2003-02-13 | Virogene Ltd. | Vectors for expressing heterologous peptides at the amino-terminus of potyvirus coat protein, methods for use thereof, plants infected with same and methods of vaccination using same |
| GB0520068D0 (en) | 2005-10-03 | 2005-11-09 | Cancer Res Technology | av peptide ligand |
-
2005
- 2005-10-03 GB GB0520068A patent/GB0520068D0/en not_active Ceased
-
2006
- 2006-10-03 CA CA2624618A patent/CA2624618C/en active Active
- 2006-10-03 EP EP06794625.1A patent/EP1957522B1/en active Active
- 2006-10-03 US US12/088,998 patent/US8383593B2/en active Active
- 2006-10-03 JP JP2008534069A patent/JP5449774B2/ja active Active
- 2006-10-03 WO PCT/GB2006/003673 patent/WO2007039728A2/en not_active Ceased
- 2006-10-03 ES ES06794625.1T patent/ES2638439T3/es active Active
- 2006-10-03 CA CA2854550A patent/CA2854550C/en active Active
-
2013
- 2013-01-17 US US13/743,714 patent/US8927501B2/en not_active Expired - Lifetime
-
2014
- 2014-12-11 US US14/567,274 patent/US9650416B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009509562A5 (https=) | ||
| ES2925098T3 (es) | Activador triple que activa el receptor de glucagón, GLP-1 Y GIP | |
| ES2548259T3 (es) | Análogo del péptido similar al glucagón-1 y uso del mismo | |
| JP2005519041A5 (https=) | ||
| Nguyen et al. | The glucose-lowering potential of exendin-4 orally delivered via a pH-sensitive nanoparticle vehicle and effects on subsequent insulin secretion in vivo | |
| ES2739613T3 (es) | Péptidos que penetran en las células y sus métodos de preparación y su uso | |
| ES2981891T3 (es) | Agonistas del receptor de GLP-1/glucagón de acción prolongada | |
| AU2015247833B2 (en) | Bi-terminal PEGylated integrin-binding peptides and methods of use thereof | |
| ES2691534T3 (es) | Derivados de exendina-4 como agonistas selectivos del receptor de glucagón | |
| US10065993B2 (en) | Peptides and peptide/active compound conjugates for renal targeting | |
| Seo et al. | In vivo biodistribution and small animal PET of 64Cu-labeled antimicrobial peptoids | |
| JP2014525901A5 (https=) | ||
| JP2008536483A5 (https=) | ||
| JP2013523618A5 (https=) | ||
| JP2016501204A5 (https=) | ||
| CN111032072A (zh) | 用于施用胰高血糖素样肽2（glp-2）类似物的剂量方案 | |
| CN103596583A (zh) | 新型胰高血糖素类似物 | |
| JP2011526886A5 (https=) | ||
| JP2013517307A5 (https=) | ||
| JP2015533833A5 (https=) | ||
| JP2010508305A5 (https=) | ||
| BRPI0613984A2 (pt) | peptìdios para uso no tratamento da obesidade, seu uso e composição farmacêutica compreendendo os mesmos | |
| JP2016515620A5 (https=) | ||
| JP2022502347A (ja) | 細胞透過性ペプチド | |
| US20230183317A1 (en) | Methods of detecting and treating lung damage in respiratory-related viral infections |